Imaging Gallery

Click to expand

Reaction:

• Powder (Calcium Phosphate salts) + Liquid (Water/Sodium Phosphate).
• Precipitation reaction -> Forms nanocrystalline Hydroxyapatite (HA) or Brushite.
• pH neutral.
• Micro-porous: Allows fluid/cell diffusion (Osteoconduction).

Types:

1. Apatite Cements: Stronger, slow resorption (years).
2. Brushite Cements: Weaker, rapid resorption (months).

• Autograft (Iliac Crest):
  • Osteogenic (cells), Osteoinductive (proteins), Osteoconductive (scaffold).
  • Risk: Donor site pain. Limited quantity.
• CaP Cement:
  • Osteoconductive ONLY.
  • Unlimited quantity.
  • High compressive strength immediately (structural).

Calcium phosphate cements are synthetic bone void fillers that mimic the mineral phase of bone (hydroxyapatite) and are osteoconductive but not osteoinductive. They set via an isothermic (non-exothermic) precipitation reaction, unlike PMMA which generates thermal necrosis risk. Key properties include high compressive strength (20-50 MPa, greater than cancellous bone) but low tensile/shear strength, making hardware protection essential. Primary applications include metaphyseal void filling in tibial plateau fractures and distal radius fractures, where they prevent articular subsidence. Over 6-18 months, osteoclasts remodel the cement and replace it with host bone through osteotransduction.

Tibial Plateau Fractures:

• Elevate depressed articular surface.
• Fill the metaphyseal void with CaP cement.
• Advantage: Unlike cancellous chips, it provides immediate structural support (high compression strength) to prevent re-collapse/subsidence before the plate takes full load.

Distal Radius:

• Void filler in elderly osteoporotic bone.

Composition

Powder Components

• Tetracalcium phosphate (TTCP): Ca₄(PO₄)₂O
• Dicalcium phosphate anhydrous (DCPA): CaHPO₄
• α-Tricalcium phosphate (α-TCP): α-Ca₃(PO₄)₂
• Calcium carbonate, calcium oxide (modifiers)

Liquid Phase

• Water or sodium phosphate solution
• pH modifiers
• Accelerators (e.g., citric acid)

Setting Reaction

Mechanism

1. Powder dissolves in liquid (acidic microenvironment)
2. Supersaturation of calcium and phosphate ions
3. Precipitation of new crystalline phase
4. Interlocking crystal network provides mechanical strength

Key Characteristics

• Isothermic: No heat generated (unlike PMMA)
• Time: 10-30 minutes working time, 24 hours for full strength
• Environment: Sets in aqueous (wet) environment

Microstructure

Porosity

• Macropores (100-500 μm): Created by incorporation techniques
• Micropores (1-10 μm): Inherent to setting reaction
• High surface area enhances osteoconduction

Crystal Structure

• Hydroxyapatite: Hexagonal crystals
• Brushite: Monoclinic crystals
• Similar to biological bone mineral

By End Product

By Form

Injectable

• Paste form, delivered via syringe
• Sets in situ after injection
• Ideal for minimally invasive application
• Examples: Norian SRS, HydroSet

Pre-formed

• Blocks, granules, or putty
• Shaped before or during surgery
• Higher initial strength

By Application

Commercial Products

• Norian SRS/CRS: Apatite cement, high strength
• ChronOS: β-TCP based, resorbable
• α-BSM: Injectable, fast-setting
• HydroSet: Brushite based, faster resorption

Primary Indications

Metaphyseal Fractures

• Tibial plateau: Schatzker II, III, VI with articular depression
• Distal radius: Metaphyseal void after reduction in osteoporotic bone
• Calcaneal fractures: Structural support of posterior facet
• Proximal humerus: Metaphyseal void filling

Tumour Surgery

• Curettage of benign bone tumours (GCT, ABC, unicameral bone cyst)
• Filling defect after tumour removal
• May be combined with autograft/allograft

Vertebral Augmentation

• Alternative to PMMA for kyphoplasty/vertebroplasty
• Lower exothermic risk but higher cost

Contraindications

Absolute

• Active infection
• Uncontained defects (cement will leak)
• Load-bearing diaphyseal sites

Relative

• Large defects requiring structural support
• Poor soft tissue coverage
• Immunocompromised patients

Compressive Strength

Tensile/Shear Strength

• CaP Cement: 2-5 MPa (very low)
• PMMA: 25-40 MPa
• Cortical Bone: 50-150 MPa

Clinical Implication: CaP cements are brittle; require hardware protection (plate, screws) in fracture treatment

Modulus of Elasticity

• CaP cements: 5-15 GPa
• Cancellous bone: 0.1-1 GPa
• Cortical bone: 15-20 GPa

Fatigue Properties

• Limited fatigue resistance
• Catastrophic failure under cyclic loading
• Not suitable for high-stress cyclical loading

Pre-operative Planning

Patient Selection

• Contained metaphyseal defect
• Adequate soft tissue coverage
• No active infection

Defect Assessment

• Size and containment
• Load-bearing requirements
• Need for structural vs void-filling

Intraoperative Considerations

Preparation

• Read manufacturer instructions carefully
• Ensure powder/liquid ratio correct
• Prepare before need (limited working time)

Working Time

• Typically 10-15 minutes
• Temperature affects setting (faster if warm)
• Must be injected before setting begins

Adjuncts

Hardware Protection

• Buttress plating for metaphyseal fractures
• Prevents shear/tensile failure
• Essential for weight-bearing bones

Combination with Biologics

• May add autograft for osteoinduction
• Platelet-rich plasma (theoretical benefit)
• BMP addition (research stage)

Tibial Plateau Example

Step 1: Fracture Reduction

• Elevate depressed articular segment
• Use bone tamp or elevator through cortical window
• Confirm reduction under fluoroscopy

Step 2: Cement Preparation

• Mix powder and liquid per manufacturer
• Achieve paste consistency
• Work within time window

Step 3: Cement Application

• Inject through cortical window or cannula
• Fill void completely (no air pockets)
• Overfill slightly (will compress)

Step 4: Hardware Application

• Apply buttress plate before cement sets
• Screws through or around cement
• Provides protection against shear forces

Step 5: Confirmation

• Fluoroscopy to confirm fill and reduction
• Check cement containment
• Assess hardware position

Key Technical Points

Containment

• Create cortical window if needed
• Block significant egress points
• May use small bone graft to contain

Bleeding Control

• Lavage defect before injection
• Blood dilutes cement, weakens setting
• Tourniquet useful if applicable

Setting Confirmation

• Wait for initial set before wound closure
• Typically 15-30 minutes
• Test with probe

Material-Related

Cement Extravasation

• Leakage into soft tissues or joint
• More common with uncontained defects
• Usually resorbs without issue (unlike PMMA)

Incomplete Fill

• Air pockets reduce strength
• May require reoperation
• Prevented by proper technique

Brittleness/Fracture

• Catastrophic failure under shear
• Requires hardware protection
• More common in brushite cements

Clinical Complications

Infection

• Not inherent to material
• Biofilm formation possible
• Requires debridement if occurs

Delayed Resorption

• Apatite cements may persist for years
• Usually asymptomatic
• May interfere with future surgery

Subsidence

• Despite cement support
• Usually due to poor technique or osteoporosis
• Hardware failure common cause

Comparison to Alternatives

📊 Management Algorithm

Click to expand

Immediate

Weight-Bearing

• Protected weight-bearing initially
• Progressive loading as bone heals
• Hardware provides protection during healing

Monitoring

• Standard wound care
• Watch for signs of extravasation
• Imaging at 2 and 6 weeks

Medium-Term

Rehabilitation

• Range of motion as tolerated
• Strengthening when fracture stable
• Progress based on clinical and radiographic healing

Imaging Follow-up

• X-rays at 6, 12 weeks
• Assess fracture healing and cement integration
• CT if concern about resorption

Long-Term

Cement Remodeling

• Brushite: 6-12 months
• Apatite: Years to decades
• Gradual replacement by host bone

Hardware Removal

• Consider once fracture healed
• Cement usually incorporated or resorbed
• Not routinely required

Clinical Outcomes

Tibial Plateau Fractures

• Reduced articular subsidence vs autograft
• Equivalent functional outcomes
• No donor site morbidity

Distal Radius Fractures

• Maintains reduction in osteoporotic bone
• Faster return to function
• Equivalent long-term outcomes

Radiographic Outcomes

Cement Incorporation

• Evidence of bone ingrowth at 6-12 months
• Progressive replacement by host bone
• Apatite cements may remain visible longer

Subsidence Prevention

• Superior to autograft for structural support
• 2-3 mm less subsidence in tibial plateau studies
• Maintains articular congruity

Functional Outcomes

Patient-Reported Outcomes

• No difference in pain scores
• Equivalent range of motion
• No donor site morbidity (vs autograft)

Return to Activity

• Similar timeframes to other grafts
• Hardware removal rates similar
• Long-term function maintained

Regulatory Status

TGA Approval

• Multiple CaP cements registered with Therapeutic Goods Administration
• Classified as Class III medical devices
• Examples: Norian SRS, ChronOS, HydroSet

Clinical Use in Australia

Major Trauma Centres

• Widely available in major hospitals
• Used per surgeon preference
• Cost consideration in some centres

Common Applications

• Tibial plateau fractures (Schatzker II-III)
• Distal radius fractures in elderly
• Calcaneal fractures

Training and Guidelines

AOA Guidelines

• No specific guidelines for CaP use
• Covered within fracture management principles
• Surgeon discretion for graft choice

FRACS Examination

• Basic science of bone substitutes commonly tested
• Comparison to PMMA important topic
• Clinical applications in trauma vivas

Cost Considerations

Hospital Perspective

• CaP cement more expensive than autograft
• Offsets donor site morbidity costs
• Variable availability in regional centres

Private vs Public

• More commonly used in private sector
• Public hospitals may limit to specific indications
• Cost-benefit analysis influences choice

1. Larsson S, Bauer TW. Use of injectable calcium phosphate cements for fracture fixation: a review. Clin Orthop Relat Res. 2002.
2. Bajammal SS, et al. The use of calcium phosphate bone cement in fracture treatment. JBJS Am. 2008.